Does rosuvastatin delay progression of atherosclerosis in people with HIV infection at moderate cardiovascular risk? A randomized, placebo-controlled trial
Phase of Trial: Phase IV
Latest Information Update: 03 Dec 2018
Price : $35 *
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- 27 Nov 2018 Planned number of patients changed from 102 to 85.
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.